Injection-site reactionsredness, swelling, minor discomfortare the most frequently reported adverse effects, occurring in 58% of users within 2448 hours post-injection
Comprehensive Medical Wellness Your health is more than weight
Kimura, I., Inoue, D., Hirano, K
SURMOUNT-2: tirzepatide with type 2 diabetes The second trial focused on adults who had both obesity and type 2 diabetes, a population that traditionally loses less weight with GLP-1 medications because insulin resistance and metabolic dysfunction create additional barriers
Author Contribution Statement The manuscript has been read and approved by all the authors and each author believes that the manuscript represents honest work
Gastrointestinal endoscopy clinics of North America